Clovis Oncology (NASDAQ:CLVSQ – Get Rating) is one of 981 public companies in the "Pharmaceutical preparations" industry, but how does it contrast to its competitors? We will compare Clovis Oncology to related companies based on the strength of its profitability, valuation, dividends, risk, institutional ownership, earnings and analyst recommendations.
Volatility & Risk
Clovis Oncology has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, Clovis Oncology's competitors have a beta of 0.87, suggesting that their average share price is 13% less volatile than the S&P 500.
Get Clovis Oncology alerts:Valuation & Earnings
This table compares Clovis Oncology and its competitors revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Clovis Oncology | $148.76 million | -$264.52 million | -0.08 |
| Clovis Oncology Competitors | $2.27 billion | $238.32 million | -5.79 |
Clovis Oncology's competitors have higher revenue and earnings than Clovis Oncology. Clovis Oncology is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Clovis Oncology and its competitors, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Clovis Oncology | 0 | 0 | 0 | 0 | N/A |
| Clovis Oncology Competitors | 3936 | 14619 | 40854 | 691 | 2.64 |
As a group, "Pharmaceutical preparations" companies have a potential upside of 116.05%. Given Clovis Oncology's competitors higher probable upside, analysts clearly believe Clovis Oncology has less favorable growth aspects than its competitors.
Profitability
This table compares Clovis Oncology and its competitors' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Clovis Oncology | -189.37% | N/A | -57.78% |
| Clovis Oncology Competitors | -3,321.46% | -193.57% | -36.38% |
Institutional and Insider Ownership
24.5% of Clovis Oncology shares are owned by institutional investors. Comparatively, 40.7% of shares of all "Pharmaceutical preparations" companies are owned by institutional investors. 4.4% of Clovis Oncology shares are owned by insiders. Comparatively, 15.7% of shares of all "Pharmaceutical preparations" companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Clovis Oncology competitors beat Clovis Oncology on 6 of the 10 factors compared.
Clovis Oncology Company Profile
(Get Rating)
Clovis Oncology, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of innovative anti-cancer agents in the United States, Europe, and additional international markets. Its U.S. marketed product, Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase (PARP), is approved for use in the maintenance treatment and treatment of eligible adult patients with recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer, and also for the treatment of adult patients with a deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC), which have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy. In Europe, Rubraca is approved for use in recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer. The company was founded by Andrew R. Allen, Gillian C. Ivers-Read, Patrick J. Mahaffy, and Erle T. Mast on April 20, 2009 and is headquartered in Boulder, CO.
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.